Immunai is a series b startup based in United States. 1 investor tracked.
Immunai is a startup founded in 2020 based in France. Its most recent tracked round is Series B. Brouky records 3 investors associated with the company.
Immunai develops an AI-driven platform that maps the human immune system to enhance drug discovery and development, utilizing multi-omic data and machine learning to predict patient responses and identify therapeutic targets.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.